SOPHiA GENETICS and AstraZeneca partner to enhance global access to liquid biopsy testing.

SOPHiA GENETICS and AstraZeneca have partnered to enhance global access to less invasive liquid biopsy testing, deploying the MSK-ACCESS® system to 20 institutions in the next year. This collaboration aims to complement solid tissue testing and generate real-world data to support cancer research. Additionally, Guardant Health and Policlinico Gemelli in Italy will establish an in-house liquid biopsy service, while Pillar Biosciences and AstraZeneca aim to improve molecular testing access in Europe.

September 10, 2024
10 Articles